Professional
Added to YB: 2026-09-24
Pitch date: 2026-08-20
ICCC [bullish]
ImmuCell Corporation
-0.99%
current return
Author Info
SRK Capital is a fund focused on concentrated value investing. Sign up for the newsletter.
Company Info
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally.
Market Cap
$90.4M
Pitch Price
$10.09
Price Target
N/A
Dividend
N/A
EV/EBITDA
12.50
P/E
133.43
EV/Sales
3.06
Sector
Biotechnology
Category
growth
SRK Fund I Portfolio Holding: ImmuCell Corporation
ICCC (hold): ImmuCell’s strong Q1 2026 underscored the earnings and cash-flow potential of First Defense following its exit from Re-Tain. Sales rose 28.4% to $10.4 million, gross margin reached 45.0%, and net income increased 34% to $1.9 million. Even after recent share appreciation, the opportunity remains compelling. Capacity expansion beyond 450,000 units monthly supports a path to $35-$40 million of sales over 12-24 months; with gross margins near 45% and the Re-Tain development burden removed, annual EBITDA can grow toward $12-$14 million.
Read full article (1 min)